Chronic dexamethasone treatment and its effects on sensory neuropeptides, pulpal injury reactions and reparative dentin.
Initial sensory nerve reactions to dental injuries include terminal sprouting and intensified immunoreactivity for calcitonin gene-related peptide (CGRP) and substance P (SP); those reactions are reduced at 4 days after injury when rats are treated daily with dexamethasone (DEX) [17]. Here we have analyzed long-term effects of DEX (daily, 0.2 mg/kg) on wound healing, sensory nerve sprouting, and CGRP/SP intensity at 7-14 days after cavity preparation. All DEX treated rats had loss of appetite and stopped growing during the postoperative periods while controls had normal postoperative growth. After 7-14 days, CGRP immunoreactivity (IR) was decreased to one-third of normal (P < 0.05) compared to vehicle in both the intact and injured molar pulp, and SP also decreased, but the neuropeptide intensity in adjacent periodontal innervation was not changed. Pulpal injury and inflammation were reduced by DEX treatment, but reparative dentin was formed just as well in the DEX rats as in the vehicle group. When the injured teeth formed fibrous dentin, there was sprouting of nerves towards that matrix, and DEX did not inhibit that reaction. The sprouts could contain intense neuropeptide immunoreactivity in DEX rats even though the CGRP/SP intensity in uninjured pulp was reduced. We conclude that (1) chronic DEX treatment causes a generalized decrease in CGRP and SP neuropeptides in pulpal nerves but not in periodontal ligament; (2) it reduces abscess formation in injured teeth; (3) it does not block reparative dentin formation; and (4) it does not block sprouting of pulpal nerves towards fibrous dentin. The selective loss of pulpal neuropeptides CGRP and SP during dexamethasone treatment may be caused by reduced dental function since there was substantial loss of appetite and chronic weight loss during the 1-2 week treatment periods.
Ferrari
A M
AM
School of Dentistry, University of Washington, Seattle 98195-7137, USA.
Byers
M R
MR
D000818:Animals; D015740:Calcitonin Gene-Related Peptide / Q000378:metabolism*; D003804:Dentin / Q000378:metabolism*; D003907:Dexamethasone / Q000494:pharmacology*; D007150:Immunohistochemistry; D008297:Male; D009475:Neurons, Afferent / Q000187:drug effects*; D009479:Neuropeptides / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013373:Substance P / Q000378:metabolism*; D014070:Tooth / Q000601:surgery
D009479:Neuropeptides; D013373:Substance P; D003907:Dexamethasone; D015740:Calcitonin Gene-Related Peptide